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Editorial on the Research Topic
Bifidobacteria and Their Role in the Human Gut Microbiota
Bifidobacteria were originally isolated by Tissier at the beginning of the last century from infant
stool samples and until now 57 (sub)species have been included in this bacterial genus (Turroni
et al., 2011; Milani et al., 2014). Bifidobacterial biology has captured increasing attention in the last
15 years due to widespread interest in using bifidobacteria as health promoting microorganisms,
i.e., known as probiotics, in the food industry. Significant efforts have been expended to dissect
the genetics as well as molecular mechanisms underlying the probiotic action(s) of bifidobacteria.
This has led to the establishment of a new scientific discipline called probiogenomics, which is
providing new insights into the diversity and evolution of bifidobacteria and to the identification of
their health-promoting effector molecules (Ventura et al., 2009; Turroni et al., 2014). Furthermore,
thanks to recent discoveries about the microbial diversity of the human gut, we have started to
achieve detailed insights about the composition of the bifidobacterial communities in this complex
ecosystem and to understand the intricate relationship with their host as well as with the other
members of the gut microbiota. Altogether, this knowledge will be crucial in order to develop novel
bacterial therapeutic strategies based on bifidobacteria.
The 21 articles comprising the Research Topic “Bifidobacteria and their role in the human gut
microbiota” illustrate the many key advances that now define our understanding of bifidobacteria-
host molecular interactions, as well as the relationship between the various members of the
Bifidobacterium genus with other residents of intestinal microbiota.
The current knowledge of the general features of bifidobacteria is reviewed, with particular focus
on the metabolic features used to colonize the human gastrointestinal tract (O’Callaghan and van
Sinderen) and on the specificmolecular mechanisms employed by thesemicroorganisms to interact
with host tissue (Ruiz et al.; Wei et al.; Westermann et al.). In addition, the compositional changes
of bifidobacterial populations associated with different stages of life are reviewed (Arboleya et al.).
Variations in the composition of the human gut microbiota and bifidobacterial communities due
to subsistence strategy, i.e., from hunter-gatherer to urban industrial Western lifestyle, has been
studied (Soverini et al.). Also, the canine gut microbiota and the contribution of bifidobacterial
taxa in this ecosystem have been explored (Sabbioni et al.).
There is growing interest in the mechanisms utilized by bifidobacteria to interact with each
other in the gut ecosystem. These include specific metabolic foraging features related to glycans
used for cross-feeding (Turroni et al.) as well as metabolic strategies used by bifidobacteria to
assimilate nitrogen in their natural ecological niche (Ferrario et al.). The current knowledge
regarding compounds that may positively influence human gut microbiota composition, such as
short-chain fatty acids (SCFAs), is reviewed (Rivière et al.). Notably, these microbial end-products
possibly allow the co-existence of bifidobacterial strains with other butyrate-producing bacteria in
the human colon.
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Another important feature of bifidobacterial physiology is
their ability to restrain pathogen growth in the intestine. This
feature is investigated by two original research articles specifically
focused on the competition with Escherichia coli O157:H7 as
well as Salmonella enterica serovar Typhimurium (Bondue et al.;
Vazquez-Gutierrez et al.), and Clostridium difficile (Valdés-Varela
et al.). Furthermore, an investigation of the anti-viral effect of
bifidobacteria toward noroviruses has been included (Li et al.).
In addition, the genomics of the order Bifidobacteriales has
been explored via a phylogenetic and comparative study on
proteins from all publicly available genome sequences belonging
to the members of this order (Zhang et al.). Such analyses
provide an in-depth overview of their evolutionary relationships
and identify molecular markers that are unique to the different
members of the order Bifidobacteriales at multiple phylogenetic
levels. Moreover, Brandt and Barrangou propose a phylogenetic
analysis of the Bifidobacterium genus using glycolysis enzyme
sequences as a typing method.
The role of the gut microbiota in metabolism and metabolic
disease risk has been described (Connolly et al.). The ecology
of bifidobacteria has been also discussed with an opinion article
focusing on the contribution of bifidobacteria to the infant gut
microbiota in humans (Tannock et al.). The efficacy of the
probiotic Bifidobacterium animalis subsp. lactis species, which
is widely used in fermented dairy products, in the management
of gastrointestinal disorders, has been investigated. In particular,
two studies have been included, one investigating the effect of
this species on intestinal barrier strength (Martín et al.) and
another analysing the mitigating role of exopolysaccharides of
B. animalis subsp. lactis in intestinal inflammatory processes
such as ulcerative colitis (Hidalgo-Cantabrana et al.). Finally,
technological strategies to preserve and protect cell viability of
probiotic bifidobacteria that are needed to guarantee the efficacy
of probiotic products are amply illustrated in this Research Topic
(Yeung et al.).
The integration of various studies to define gut microbiota
composition coupled with detailed analyses of the physiology and
genomics of bifidobacteria will be crucial in order to improve
our understanding of the complex interactions occurring in
the human gut. Altogether, these data will undoubtedly help
in developing the industrial use of bifidobacteria including for
therapeutic use.
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